Dj Icad Collaborates With Microsoft To Provide Access To Its Mammography Solutions In Microsoft's Precision Imaging Network

NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) — iCAD, Inc. (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD’s ProFound Breast Health Suite on Microsoft’s Precision Imaging Network. The iCAD and Microsoft collaboration provides access to automated radiology mammography reporting for patients through Microsoft’s advanced radiology reporting platform, PowerScribe. iCAD’s ProFound AI® Breast Health Suite will be fully cloud-hosted across Microsoft’s extensive network, providing radiologists and healthcare providers with streamlined, AI-driven insights that help to elevate breast health detection, enhance clinical workflows, and ultimately aim to improve patient outcomes.

A majority of radiologists across the U.S. rely on PowerScribe, for its AI-based radiology reporting and workflow capabilities. As a mammography solution offered through Precision Imaging Network, iCAD will be uniquely optimized for integration within PowerScribe to enable radiologists to efficiently create, review, and share diagnostic reports, leveraging features that standardize language and automate routine tasks. Precision Imaging Network securely hosts third-party AI models with standardized integrations into radiology workflows.

“We are excited to partner with Microsoft to expand access to our AI solutions for breast cancer detection across a broader network of healthcare providers,” said Dana Brown, CEO and President of iCAD. “This collaboration supports our growth strategy by expanding the reach of our industry-leading technology, driving deeper market penetration, and advancing our transition to a SaaS model. Integrating ProFound AI results in the PowerScribe report aligns with our shared mission to improve cancer detection and care while empowering radiologists to deliver earlier, more accurate interpretations with greater confidence and efficiency.”

“With the integration of iCAD’s ProFound suite of breast health offerings with our Precision Imaging Network and PowerScribe solutions, we will help provide radiologists and patients with more accurate, actionable breast health insights, while streamlining mammography screening workflow, driving clinical and operational value at scale.” said Vikram Chhabra, General Manager, Diagnostic Solutions at Microsoft.

Precision Imaging Network provides streamlined access to a curated collection of third-party AI models through a single point of integration, empowering radiologists and healthcare systems to leverage AI insights directly within existing clinical workflows. Connecting over 17,000 healthcare facilities nationwide, Precision Imaging Network seamlessly integrates iCAD’s ProFound AI® technology, making it readily available to radiologists and specialty physicians across diverse healthcare environments. By embedding iCAD’s capabilities in cancer detection and density assessment, Precision Imaging Network delivers targeted, patient-specific insights with unprecedented efficiency.

This collaboration follows recent FDA clearance of iCAD’s ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT), marking a new era in AI-powered breast cancer detection. This fourth-generation AI solution utilizes advanced deep learning convolutional neural networks, achieving a 22% improvement in detecting complex and aggressive cancer subtypes over previous versions, with significant enhancements for dense breast tissue. ProFound Detection Version 4.0 is specifically designed to navigate the intricacies of DBT exams, achieving an 18% reduction in lesion markings to minimize potential false positives and streamline radiologists’ workflows. The solution also incorporates priors into the AI analysis, allowing radiologists to better assess changes over time, further supporting more accurate, personalized patient screening assessments.

iCAD will showcase this next-generation AI collaboration, along with its end-to-end breast health AI suite and the recently cleared ProFound Detection Version 4.0, at the upcoming 2025 SIIM25 Annual Meeting + InformaticsTECH Expo in Portland, OR from May 21st to May 23rd. Visit iCAD’s event page to learn more and book a live demonstration: https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/siim-2025/.

About iCAD, Inc.

iCAD, Inc. is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis.  For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

CONTACTS

Media Inquiries:

pr@icadmed.com

Investor Inquiries:

John Nesbett/Rosalyn Christian

IMS Investor Relations

icad@imsinvestorrelations.com

By Mackenzie Tatananni

Stock futures were mixed on Tuesday after the Dow Jones Industrial Average and S&P 500 each notched a five-day winning streak.

These stocks were poised to make moves Tuesday:

General Motors stock fell 3.1% after the auto maker withdrew its 2025 profit guidance citing uncertainty. Ford Motor edged 0.5% lower after both stock were initially higher. Trump is set to restructure tariffs so that they no longer stack on top of each other. Companies paying auto tariffs would no longer be charged for other levies, including those on steel and aluminum.

Tesla fell 0.5% after initially rising ahead of President Donald Trump's auto tariffs announcement. The president is expected to unveil changes to his tariff policy later today, which could give shares a boost. While Tesla doesn't import cars to the U.S., the electric-vehicle maker still faces tariffs on imported parts.

Coca-Cola was down 0.1%. The soda maker is set to report earnings before markets open Tuesday. Analysts are anticipating earnings of 72 cents a share, flat from the previous year. Sales are expected to come in at $11.16 billion, down from $11.30 billion a year ago. The company faces a challenging macro as Americans pull back from spending due to inflationary pressure and recession fears.

JetBlue rose 1% ahead of earnings. Peers have reported a slowdown in domestic demand, counterbalanced by strength in international and premium travel. JetBlue, for one, remains heavily exposed to the U.S. market. Macroeconomic uncertainty is also expected to take a hit on the company's financials. Analysts see the airline reporting a loss of 63 cents per share on sales of $2.14 billion in the first quarter.

Pfizer was up 0.1%. Analysts are expecting the pharmaceutical giant to report earnings of 67 cents a share on sales of $13.9 billion in the first quarter. Pfizer faces a challenging recovery, as the stock sits at levels it hasn't seen since 2012. The company announced April 14 that it was dropping its oral obesity drug candidate danuglipron over concerns about liver damage risk.

Wolfspeed was up nearly 15%. Shares of the semiconductor manufacturer ended the session up 26% on Monday. These sharp gains were likely the result of a so-called short squeeze, in which the price of a heavily shorted stock rises suddenly, forcing short sellers to buy back shares to cover their positions.

Nvidia was down 0.2%. The chip maker closed down 2.1% on Monday. Shares fell on a report that Huawei was planning to test its Ascend 910D artificial-intelligence chip, styled as an answer to Nvidia's H100, with domestic Chinese customers. Big tech earnings, expected this week, are seen as the next catalyst for Nvidia stock, as investors look for indications of a pullback in data-center spending.

Meta Platforms was up 0.4%. The Instagram and Facebook owner is set to report earnings on Wednesday, along with Microsoft, shares of which were up 0.4%. Apple and Amazon.com are slated to report earnings on Thursday. The stocks were up 0.3% each in premarket trading Tuesday.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

While the first 100 days of Donald Trump's Presidency have been dismal for stock markets, the next 100 could be crucial-and things are starting to look brighter.

The S&P 500 has fallen 7.8% since Trump took office in January — on track for the worst start to a presidency since Richard Nixon's second term in 1973, according to Dow Jones Market Data.

But the period is ending on a strong note after the index notched its fifth consecutive day of gains Monday, the longest winning streak this year.

The next 100 days should feature several deals between the U.S. and its major trading partners. It's already day 20 of Trump's 90-day pause on reciprocal tariffs but Treasury Secretary Scott Bessent said Monday that deals with India and South Korea are close.

There are more signs of tariffs being eased--Trump is expected to water down auto levies Tuesday and Bessent said it was up to China to de-escalate trade tensions between the world's two largest economies. Both sides appear open to working things out.

While tax cuts may materialize in the summer, lifting consumers' finances, the impact of tariffs will likely start to hurt them sooner, hitting shoppers and the economy hard--unless the White House rows back considerably on the levies it has announced so far.

There's still time to avoid the worst of the damage. Corporate earnings so far paint a picture of uncertainty, rather than one of disaster--and the same can be said for economic data.

Earnings from four of the so-called Magnificent Seven megacap stocks--Meta, Microsoft, Amazon and Apple--will kick off the next 100 days. If the Big Tech momentum started by Alphabet last week can continue, then the market's recovery can gather pace.

Ultimately, though, trade developments will dictate the market moves. After 100 days of nasty surprises, some pleasant ones may be on the way.

• Callum Keown

***

Tariff Revenue So Far Falls Short of President's Number

President Donald Trump has boasted that his import tariffs are bringing in $3 billion of revenue a day, suggesting they could one day replace income taxes. But the Treasury's daily statements show much lower tariff receipts, certainly not enough to replace the billions a day collected in individual income tax.

• Since tariffs rates were raised to current levels on April 9, the U.S. has collected $14.7 billion in revenue from imports. While that's a 135% jump from the same time in 2024 and higher than import revenue in March, it adds up to a daily average of $918 million, or less than one-third of Trump's estimate.
• Individual income tax totaled $6.6 billion a day last year. To reach that, tariffs would have to be 74%, which would effectively cut off trade and thus blunt tariff collections. Tariffs are currently set at 10% across the board, 25% for certain products, and 145% for goods from China.
• Main Street is reacting to tariffs and Trump's trade war by cutting jobs and slowing hiring, Hasbro is cutting $1 billion in costs, and Dow has postponed capital spending because of tariff uncertainty. Norfolk Southern CEO Mark George said the company is trying to "control the controllables."
• Chinese goods exported to the U.S. are expected to contract by two-thirds this year if tariffs are maintained, according to a Goldman Sachs report. Goods from the communication equipment, apparel, and chemical product sectors represent a high share of China's U.S.-bound goods.

What's Next: The White House is expected to unveil details about what negotiations with countries like India and South Korea have produced as it tries to de-escalate Trump's trade war. But any "deals" it announces aren't likely to ease the worry over tariffs that has shaken financial markets.

• Adam Levine, Adam Clark, Reshma Kapadia, and Janet H. Cho

***

Congress Returns With Tax Cut Bill as Its Top Agenda Item

Congressional Republicans and President Donald Trump have promised to slash taxes, reduce the deficit, and avoid making substantial cuts to programs such as Medicaid and Medicare. Now they're going to have to reconcile those commitments, and the most likely casualty will be reducing the federal debt.

• Congress returned from break on Monday. The Republican agenda's top item is a bill to extend the tax cuts for individuals that were originally included in Trump's 2017 tax law. House Republicans hope to finish it by Memorial Day, while Senate leaders don't plan to finish their version before July.
• To get to this point, Speaker Mike Johnson (R., La.), Senate Majority Leader John Thune (R., S.D.), and Trump had to thread the needle between fiscal hawks concerned about the burgeoning federal debt, at about $37 trillion, and moderates concerned about cutting Medicaid or Medicare.
• Lawmakers will likely seek steep budget cuts anyway. One likely suspect is Medicaid. House Republicans are seeking more than half of proposed $1.5 trillion in cuts from programs that are overseen by the House Committee on Energy and Commerce, which oversees that program and Medicare.
• House Minority Leader Hakeem Jeffries (D, N.Y.) said Monday that Democrats remain strongly opposed to cuts to Medicaid and food assistance and plan an aggressive push back to the GOP proposals. He scheduled a speech for Wednesday morning outlining his blueprint.

What's Next: Later this week, the Treasury is expected to give an update on when it expects to exhaust its authority to issue more debt. That will give a de facto deadline to Congress for when it needs to pass the tax bill, which will also include a provision to raise the federal debt ceiling.

• Joe Light and Liz Moyer

***

BP Cuts Stock Buybacks. Earnings Are Warning for Exxon, Chevron.

Four of the biggest oil companies are reporting earnings this week. The first, London-based BP, didn't make a great start as it reduced its share buyback program after a big drop in earnings.

• BP, which is being pressured by activist investor Elliott Management, reduced its buyback plan to $750 million a quarter from $1.75 billion. That will bolster the company's balance sheet, which is carrying a relatively high debt load. But investors were disappointed, which hurt the share price in early trading.
• Part of the drop in earnings was down to lower oil prices, which will hurt all the majors including Exxon and Shell, but BP also has its own homegrown problems. It's trying to catch up to the profitability of peers after languishing for the past five years.
• CEO Murray Auchincloss has a plan to focus on more oil and gas production, a reversal of the previous strategy that called for lower fossil fuel output and more spending on low-carbon energy sources. He also wants to lift free cash flow by 20% a year.
• He's running out of time. Elliott has built a stake of more than 5% and is pushing for more aggressive targets for cash-flow, cost cuts, and capital expenditure.

What's Next:The bigger question for the energy industry is how to respond to the 20% drop in crude prices over the past year, and there's little sign of a pickup with the economic outlook clouded by tariffs. Exxon, Chevron, and Shell all report earnings on Friday.

• Brian Swint

***

IBM Pledges to Spend $150 Billion on U.S. Manufacturing

International Business Machines will invest $150 billion in the U.S. over the next five years, including spending more than $30 billion in research and development to make mainframe and quantum computers as tariffs threaten to increase the cost of making those products overseas.

• IBM currently makes mainframes in Poughkeepsie, N.Y., and operates a fleet of quantum computers, a growing sector of the software industry. The software company said its investment reaffirms its commitment to U.S. innovation and economic opportunity.
• IBM's announcement follows billions of dollars in announced spending increases by companies including Apple, Nvidia, and Taiwan Semiconductor Manufacturing Co., as the Trump administration pushes corporate America to bring more product manufacturing to the U.S.
• IBM sees a big opportunity in quantum computing, which it says represents one of the biggest technology platform shifts in decades and will be able to solve problems that today's conventional computers cannot solve. It is also rolling out its next-generation mainframe computer with artificial intelligence features.
• The Department of Government Efficiency's cost-cutting drive resulted in the cancellation of some of IBM's government contract work, IBM executives acknowledged last week. The cancellations represent about $100 million of order backlog.

What's Next: IBM isn't the only tech giant navigating the administration's tariff policies. Dutch chip maker NXP Semiconductors said it is facing a "very uncertain" environment influenced by tariffs. It forecasts second-quarter revenue will fall from 4% to 10% from a year ago after first-quarter revenue fell 9%.

• Tae Kim and Janet H. Cho

***

This Start-Up Aims to Upend Defense Like Tesla Did for Autos A defense start-up called Anduril is aiming to do to Lockheed Martin what Tesla did to Ford Motor. It seeks to put autonomy and software at the core of its products, as Tesla has done in upending the auto industry. It might disrupt the entire defense business along the way.

• The company was established in 2017 and is now valued at more than $30 billion. The core of its technology is an AI brain called Lattice, used in its drone-tracking Sentry tower, its Ghost reconnaissance drone, its Roadrunner interceptor drone, and the autonomous unmanned aircraft Fury.
• Executive Chairman Trae Stephens once worked at Palantir Technologies, which was trying to sell software to the Defense Department. In 2013, Stephens joined the Founders Fund, the Silicon Valley venture capital fund co-founded by Peter Thiel, and was given the task of finding another Palantir or SpaceX.
• Anduril has the money required to grow and has no immediate plans to go public, Stephens says. It is still relatively small. Total contract awards from the U.S. government amount to $1.1 billion, according to publicly available government databases. The comparable number for Lockheed is $750 billion.
• For fiscal year 2024, Anduril won some $640 million in contract awards. Lockheed added $39 billion to its total. But public databases exclude classified contracts. A person familiar with the company's business says Anduril has amassed some $4 billion in contract awards, with a goal to triple that in three years.

What's Next: Lockheed had no comment about the new competition. Vertically integrated large-scale manufacturing is part of Anduril's strategy. In January, it said that Columbus, Ohio, will be the location of Arsenal-1, its first so-called hyperscale factory. For the full article, read here.

• Al Root

***

• Newsletter edited by Liz Moyer, Patrick O'Donnell, Rupert Steiner

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.